Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness - WSB-TV
10 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
What happened
"Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness - WSB-TV" is generating significant coverage in the Health category, with 11 articles from 10 distinct sources tracked by Newsylist so far.
Outlets currently covering the story include WSB-TV, NewsNation, MedPage Today and PR Newswire. Newsylist measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by Newsylist's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by Newsylist's extractive engine from coverage metadata only — no AI-written claims. Updated 43d ago.
Coverage (11)
- Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness WSB-TV · 46d ago broke it first
- GLP-1 drugs connected to rare vision issue, researchers say NewsNation · 46d ago
- GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits MedPage Today · 46d ago
- Parker Waichman LLP Comments on Growing Public Attention Surrounding GLP-1 Vision Loss Litigation PR Newswire · 46d ago
- GLP-1 RA Use Linked to Higher Risk for Ischemic Optic Neuropathy Endocrinology Advisor · 46d ago
- GLP-1 Drugs Do Not Increase NAION Risk in Patients With Optic Disc Drusen Ophthalmology Advisor · 46d ago
- GLP-1 Receptor Agonist Use Linked to Higher Risk for Ischemic Optic Neuropathy Renal and Urology News · 46d ago
- New Analysis Links Wegovy to a Rare Eye Condition That Can Cause Sudden, Permanent Vision Loss Medical Daily · 46d ago
- Study Links GLP-1 Medications To Rare Vision Issue U.S. News & World Report · 46d ago
- Link Between NAION and Ozempic, Wegovy Will Be Focus of Early Discovery in GLP-1 Vision Loss Lawsuits AboutLawsuits.com · 46d ago
- Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness WSB-TV · 46d ago broke it first
Questions people are asking
Why is "Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and " trending?
Because 10 independent news sources published 11 articles about it in a short window — a coverage burst Newsylist classifies as a trend.
How does Newsylist measure this trend?
Newsylist scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
Report: Rashod Bateman faces three charges from June incident with ex-girlfriend
Ravens wide receiver Rashod Bateman faces three charges following a June arrest in Georgia stemming from an alleged dispute involving an ex-girlfriend.
Researchers find new benefits, risks in GLP-1 weight loss drugs
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
Georgia financial CEO Todd Burkhalter sentenced for running historic $380M Ponzi scheme to fund lavish lifestyle
Drive Planning CEO Todd Burkhalter received a 20-year prison sentence for orchestrating a historic $380 million Ponzi scheme.
Tiffany Haddish Pleads Guilty to Georgia DUI
Tiffany Haddish pleads guilty in a 2022 Georgia DUI case, avoiding trial and jail time.
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.